Tandem Diabetes Care (TNDM) Net Income towards Common Stockholders (QoQ) (2013 - 2026)
Tandem Diabetes Care (TNDM) Net Income towards Common Stockholders (QoQ) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Tandem Diabetes Care | 1.17 Bn | 597.96 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,656.91% |
| Dec 31, 2025 | 97.43% |
| Sep 30, 2025 | 59.63% |
| Jun 30, 2025 | 59.86% |
| Mar 31, 2025 | -17,398.01% |
| Dec 31, 2024 | 103.25% |
| Sep 30, 2024 | 24.66% |
| Jun 30, 2024 | 27.89% |
| Mar 31, 2024 | -42.59% |
| Dec 31, 2023 | 9.08% |
| Sep 30, 2023 | 7.79% |
| Jun 30, 2023 | 71.15% |
| Mar 31, 2023 | -679.69% |
| Dec 31, 2022 | 67.54% |
| Sep 30, 2022 | -225.24% |
| Jun 30, 2022 | -2.11% |
| Mar 31, 2022 | -236.93% |
| Dec 31, 2021 | 87.33% |
| Sep 30, 2021 | 43.65% |
| Jun 30, 2021 | 178.43% |